Why MultiplechoiceS?

MS requires MultiplechoiceS.1
MS is a disease with MultiplefaceS. From its individual presentations to the hidden ways it hits, no two patients have the same experience of MS.2–5

MS strikes early. Even in mild disease, patients report cognitive difficulties and fatigue as the main reasons for reduced work productivity, which further declines as disability progresses. Costs to society increase.6

MS is a journey with MultiplepathS. Every person with MS has an individual therapeutic need. Because of its chronic nature, patients must be treated continuously, and their medication reviewed at multiple points in time.4,9,11-13

That’s why we believe in the need for MultiplechoiceS to successfully manage this disease and tailor treatment to the unique needs of every individual.11

40 years of scientific expertise allow us to offer a portfolio of choice to achieve personalised control at multiple stages of the MS journey – helping you find the right treatment for the right patient at the right time.3,9-11

References

  1. Scolding N, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015; 15(4): 273-279.
  2. Embrey N. Multiple sclerosis: managing a complex neurological disease. Nurs Stand. 2014; 29(11): 49-58.
  3. Disanto G, et al. Heterogeneity in multiple sclerosis: scratching the surface of a complex disease. Autoimmune Dis. 2011; 932351: doi:10.4061/2011/932351.
  4. Lucchinetti C, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000; 47(6): 707-717.
  5. Penner IK. Evaluation of cognition and fatigue in multiple sclerosis: daily practice and future directions. Acta Neurol Scand. 2016; 134 Suppl 200: 19-23.
  6. Kobelt G, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017; 23(8): 1123-1136.
  7. Goldenberg MM. Multiple sclerosis review. PT. 2012; 37(3): 175-184.
  8. Coles A. Newer therapies for multiple sclerosis. Ann Indian Acad Neurol. 2015; 18(Suppl. 1): S30-S34.
  9. Gajofatto A and Benedetti MD. Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World J Clin Cases. 2015; 3(7): 545-555.
  10. Plavina T, et al. Natalizumab’s effects on peripheral immune cells in patients with multiple sclerosis (MS) are reversible by 16 - 20 weeks after treatment discontinuation. Poster P5.408. Presented at: The 68th Annual Meeting of the American Academy of Neurology (AAN). April 15-21, 2016, Vancouver, Canada.
  11. Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017; 264(12): 2351-2374.
  12. Girouard N, Soucy N. Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents. Patient Prefer Adherence. 2011; 5: 101-108.
  13. Lee A, Pike J, Edwards MR, et al. Quantifying the benefits of dimethyl fumarate over β interferon and glatiramer acetate therapies on work productivity outcomes in MS patients. Neurol Ther. 2017; 6(1): 79-90.